For years, if you asked me “is there a pill version of these weight-loss drugs?”, the honest answer was no, not really. That changed twice, four months apart. If you haven’t been following closely, the options today look nothing like they did two years ago.

A quick note on names first, since patients ask me this a lot. The Lilly drug some people have heard called “Fonday-o” is orforglipron. The FDA approved it on April 1, 2026, under the brand name Foundayo (1). Before that, on December 22, 2025, the FDA approved a 25 mg oral semaglutide tablet under the Wegovy name (2). GLP-1 medicines help control appetite and blood sugar, and that tablet was the first pill version of one approved for long-term weight management. Both are real, both are approved, and both can be prescribed today.

Both full prescribing labels are now public, and they differ in ways that decide the choice for a lot of people. Most of those differences have nothing to do with how much weight each one takes off.

Why the two pills work so differently in your body

Semaglutide is a peptide, which is a small chain of amino acids, the building blocks of proteins. Your stomach is very good at breaking down peptides, which is exactly why semaglutide originally had to be given as a shot.

Novo Nordisk’s solution was to add an ingredient called SNAC that helps the drug get absorbed before your stomach destroys it. According to a review in the journal Clinical Diabetes, SNAC does three things at once (3). It changes the local acidity around the tablet as it dissolves, it briefly protects the drug from a stomach enzyme called pepsin, and it helps the drug cross the stomach lining into your bloodstream. The absorption happens in the stomach itself rather than the intestines, which is unusual for a pill. The drug essentially enters your body right where the tablet is sitting against your stomach wall.

That trick comes with a catch, and the label is specific about it (4). You take the tablet on an empty stomach in the morning with no more than four ounces of plain water. No other liquids. Swallow it whole, and wait at least 30 minutes before you eat, drink anything, or take any other oral medication.

Thirty minutes. Every morning. Before coffee.

Orforglipron works completely differently. It is a small molecule, meaning a stable chemical rather than a fragile peptide chain. It belongs to the same drug family, mimicking a natural gut hormone that reduces appetite, but with no peptide to protect it needs no absorption booster and carries no timing ritual. Its label says to take it once daily with or without food, and specifies no water restriction and no waiting period (5). For someone who works nights, or who already swallows six other pills at breakfast, that is the whole ballgame.

What the labels actually say, and why the number in your news feed is wrong

Most of the figures circulating online come from journal publications and press releases rather than from the approved labels. The label numbers are the ones your prescription is based on, so those are the ones I use.

For Wegovy tablets, the label reports a 64-week trial in 205 adults on the tablet against 102 on placebo, all with obesity or overweight plus a weight-related condition, with diabetes excluded (4). Average weight change was 13.6 percent down on the tablet and 2.4 percent down on placebo, a difference of 11.2 percentage points. Broken out by how much people lost: 76.3 percent lost at least 5 percent of their body weight versus 31.3 percent on placebo, 59.8 percent lost at least 10 percent versus 14.4 percent, 47 percent lost at least 15 percent versus 5.5 percent, and 27.9 percent lost at least 20 percent versus 3.1 percent.

For Foundayo, the label reports a 72-week trial in 3,127 adults without diabetes (5). Average weight change was 7.4 percent down at the 5.5 mg dose, 8.3 percent down at 9 mg, and 11.1 percent down at the maximum 17.2 mg dose, against 2.1 percent down on placebo. At 17.2 mg, 35.9 percent of patients lost at least 15 percent of their body weight, compared with 6 percent on placebo.

Put those side by side and the semaglutide tablet looks better, and I would be careful with that read. Different patients, different trial lengths, different placebo responses, and nobody randomized the same people to both. What is harder to wave away is the size of each evidence base. The semaglutide tablet’s label efficacy rests on 205 treated patients. Foundayo’s rests on 3,127. Both cleared the FDA, so both met the bar, but I have more confidence in how a drug behaves across a wide range of real people when the number in the trial is measured in thousands.

Here is the detail that confuses almost everyone who reads the news coverage. The approved Foundayo strengths are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, stepped up roughly every 30 days. The trial used a capsule at 1, 3, 6, 12, 24, and 36 mg. Those map onto each other in order, so the 17.2 mg tablet you can actually be prescribed is the 36 mg dose you read about. If your maximum dose sounds far smaller than the headline, that is why.

One thing I noticed reading the Foundayo label closely: the 14.5 mg strength is approved and dispensable, and it does not appear in the label’s efficacy table at all. You can be prescribed a dose with no published average weight loss attached to it. Not dangerous, just worth knowing if you end up parked there.

The only comparison anyone has run, and who paid for it

There is still no head-to-head trial of these two drugs in obesity. There is now an indirect comparison, published in Diabetes, Obesity and Metabolism in August 2026, which pulled individual patient data from the semaglutide tablet trial and aggregate data from the orforglipron trial and statistically adjusted for differences in sex, body weight and glucose status between the two populations (6).

It found oral semaglutide 25 mg ahead by 3.2 percentage points of body weight (95% confidence interval 5.9 to 0.4) and reported higher discontinuation with orforglipron, with an odds ratio of 4.1 for stopping due to any adverse event and 13.9 for stopping due to gastrointestinal side effects.

Five of the authors are Novo Nordisk employees and shareholders, two more work for a consultancy Novo paid to run the analysis, and Novo makes the drug that won. That does not make the result false. It does mean I apply a discount. The direction is plausible and roughly matches the gap between the two labels. The magnitude I would not quote to a patient as fact. And that gastrointestinal odds ratio of 13.9 has a confidence interval running from 2.0 to 96.0, which is another way of saying the study could not pin it down.

There is one true head-to-head, and it points the other way. In adults with type 2 diabetes, orforglipron beat oral semaglutide on weight loss (7). That trial used semaglutide at 7 mg and 14 mg, well under the 25 mg weight-management dose, in a different population, for a different purpose. It answers a different question than the one you are asking.

Birth control is the difference nobody mentions

This is the most actionable difference between the two drugs and it almost never comes up in the coverage.

The Foundayo label instructs patients on oral hormonal contraceptives to switch to a non-oral method, or to add a barrier method for 30 days after starting the drug and for 30 days after every dose escalation (5). Count the escalations. With six strengths, somebody climbing to the top dose is looking at several separate 30-day windows where their pill alone is not considered reliable. Non-oral hormonal contraception is not expected to be affected.

The Wegovy tablet label carries no equivalent instruction. Its pharmacokinetic studies found no clinically significant interaction with ethinyl estradiol and levonorgestrel (4).

For a woman in her twenties or thirties on a combined oral contraceptive who does not want a pregnancy, that single difference outweighs three percentage points of average weight loss. I bring it up before either drug gets prescribed, not after.

The other interactions that quietly decide this

Orforglipron is cleared through CYP3A4, and the label puts real fences around that (5). On a strong CYP3A4 inhibitor, the maximum Foundayo dose drops to 9 mg. Clarithromycin raised orforglipron exposure 3.5-fold in a study. Going the other way, carbamazepine cut exposure by 82 percent and efavirenz by 61 percent, so strong inducers are to be avoided and moderate ones need the dose pushed up while you watch whether it still works. Strong inhibitors that also block OATP1B, ritonavir being the example the label gives, are to be avoided outright. And simvastatin is capped at 20 mg a day alongside it.

The semaglutide tablet has a shorter list but one that matters in my practice. A single 600 mcg dose of levothyroxine taken with it produced a 33 percent rise in total thyroxine exposure (4). Add the 30-minute rule on top, which pushes every other morning medication back, and a patient on thyroid replacement plus a few other dailies has a genuine scheduling problem.

If someone comes to me on carbamazepine, or on ritonavir-boosted therapy, Foundayo is awkward enough that I start elsewhere. If someone is on levothyroxine and already struggles to take it correctly, I think hard before adding a second pill with its own empty-stomach window.

Side effects

Both drugs hit the gut, and both labels say so plainly.

Foundayo’s pooled safety data runs nausea at 26 percent, 34 percent and 35 percent across the 5.5, 9 and 17.2 mg doses against 10 percent on placebo (5). Vomiting climbs from 13 to 24 percent against 4 percent. Constipation runs 20 to 27 percent against 9 percent, and diarrhea 21 to 25 percent against 11 percent. Hair loss shows up at 4 to 5 percent against 2 percent, which patients ask me about more than the numbers would suggest.

The Wegovy tablet label describes side effects similar to the injection, and adds a few tablet-specific figures (4). Just under 7 percent of patients stopped the drug for an adverse reaction, against about 6 percent on placebo. Severe gastrointestinal reactions occurred in 2 percent of tablet patients and no placebo patients. Dysesthesia, meaning abnormal or unpleasant sensation, was reported in 5 percent of tablet patients and in nobody on placebo. That last one is not something I had on my radar before reading the label, and it is worth mentioning to a patient who calls about odd skin sensations rather than writing it off.

Both drugs carry a boxed warning about thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 (4)(5).

If you have heart disease, the answer is already made

Wegovy tablets carry an approved indication to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight (4). The wording is identical to the injection’s.

Foundayo has no cardiovascular outcome indication. Its cardiovascular outcomes trial has not reported.

For a patient who has already had a heart attack or a stroke, that settles it. I go to semaglutide, and the only remaining question is tablet or injection.

How I actually choose

If you are the patient reading this, the useful question is not which drug is stronger. It is which one you will still be taking in a year. The 30-minute waiting period for the semaglutide tablet sounds minor when we talk it through on a video visit, and it trips people up in real life. I have watched patients lose ground on oral semaglutide because weekday mornings made the timing rules impossible to follow, and the drug cannot work from inside the bottle. If your mornings are chaotic, say so out loud when we talk. That is clinical information, not an excuse.

If you are a prescriber, I would frame the choice around four things before efficacy. Established cardiovascular disease points to semaglutide on the label. An oral contraceptive points away from orforglipron, or at least commits you to counseling a barrier method through every escalation. A CYP3A4 problem, especially an enzyme inducer, makes orforglipron hard to dose. Levothyroxine and a crowded morning pill box make the semaglutide tablet hard to take. What is left after those four filters is usually a clear answer, and in my experience the efficacy gap is the least useful thing to lead with.

What this costs right now

Both manufacturers run tiered self-pay pricing that starts low at the smallest dose and rises as you titrate up, and both have promotional rates on their lower strengths that are scheduled to end on December 31, 2026. Because these terms change faster than I can keep a blog post current, check the two official pages directly rather than trusting a number you read anywhere, including here: LillyDirect for Foundayo (8) and NovoCare for Wegovy (9).

What I can tell you from prescribing both is operational. I haven’t run into a prior-authorization fight or a stocking problem with Foundayo yet. Most of what I prescribe goes through LillyDirect on cash pay, because it has been one of the cheaper options on the table. Patients who have real insurance coverage tend to ask for injectable Wegovy or Zepbound instead, and I do not talk them out of it. For a fuller breakdown of cash prices across the whole class, including the injections, see my separate post on cash pay options.

The Bottom Line

Two pills, both approved, both effective, and the deciding factors are mostly not about weight loss. The semaglutide tablet takes off a bit more weight in the label data, carries a cardiovascular indication, and demands an empty stomach and a 30-minute wait every single morning. Foundayo asks nothing of your schedule, has a far larger trial behind it, and brings a contraception instruction and a list of drug interactions that rule it out for some people entirely.

Bring your actual medication list and your actual morning routine to the visit. Those two things will pick the drug faster than any comparison chart.

Related Reading

How Do I Switch From Compounded Semaglutide or Tirzepatide to Wegovy or Zepbound?

Wegovy and Zepbound Cash Pay Prices Without Insurance

Wegovy 7.2 mg: Who Should Consider the Higher Dose?

Weight Loss Drug Side Effects and How Common They Are

What Happens If You Stop Taking a GLP-1?

Doctor Supervised Weight Loss: What Works Long Term

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

1. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss (Eli Lilly): https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

2. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults (PR Newswire): https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html

3. Current Understanding of SNAC as an Absorption Enhancer: The Oral Semaglutide Experience (Clinical Diabetes, American Diabetes Association): https://diabetesjournals.org/clinical/article/42/1/74/153538/Current-Understanding-of-Sodium-N-8-2

4. WEGOVY (semaglutide) injection and tablets, US prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

5. FOUNDAYO (orforglipron) tablets, US prescribing information (Eli Lilly): https://uspl.lilly.com/foundayo/foundayo.html

6. Michalak W, Bøg M, Bendixen T, Chowdhury R, Cowley P, Laugesen C, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes, Obesity and Metabolism. 2026;28(8):7247-7256: https://pubmed.ncbi.nlm.nih.gov/42225305/

7. Orforglipron Outperforms Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial (AJMC): https://www.ajmc.com/view/orforglipron-outperforms-oral-semaglutide-in-head-to-head-type-2-diabetes-trial

8. Foundayo self-pay pricing (LillyDirect): https://www.lilly.com/lillydirect/foundayo

9. Wegovy self-pay pricing (NovoCare): https://www.novocare.com/

10. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (New England Journal of Medicine, ATTAIN-1): https://www.nejm.org/doi/full/10.1056/NEJMoa2511774